Dr. Ruella treats patients affected by hematological cancers and specializes in immunotherapy approaches. His laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CAR T) immunotherapies to rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma. Dr. Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania and in 2025 he obtained his tenure as Associate Professor.